Literature DB >> 9818975

Penicillin-resistant Streptococcus pneumoniae in Colombia: presence of international epidemic clones. Colombian pneumococcal study group.

E Castañeda1, I Peñuela, M C Vela, A Tomasz.   

Abstract

The global spread of multidrug-resistant Streptococcus pneumoniae clones is well documented in the literature. A study to determine type distribution and antimicrobial susceptibility of invasive pneumococcal isolates from Colombian children under the age of 5 was conducted from 1994 to 1996. Health centers in Santa Fe de Bogota, Medellin, Cali, and other cities collected 409 Streptococcus pneumoniae isolates. Diminished susceptibility to penicillin (DSP) was 15.6%; from these, 11.5% showed intermediate-level resistance (ILR) and 4.1% showed high-level resistance (HLR). Fifty-nine of the DSP isolates were examined by pulse field gel electrophoresis (PFGE). Capsular isolate types were 23F (54%), 14 (24%), 19F (10%), 6B (7%), 9V (3%), and 34 (2%). PFGE analysis revealed that 8 isolates shared the Spanish/USA international clone's characteristic features: PFGE pattern type A, serotype 23F; 87.5% exhibited HLR for penicillin, and all were resistant to trimethoprim/sulfamethoxazole (TMP-SMX), tetracycline, and chloramphenicol. Another 7 isolates showed the French/Spanish international clone's features: PFGE pattern type B, 2 of them being serotype 9V; and 5 type 14; HLR to penicillin was 71%, and all proved resistant to TMP-SMX. A large cluster of 24 isolates (41% of all isolates examined) shared a common PFGE type C, with 14 subtypes; all but one, serotype 34, were serotype 23F and had ILR to penicillin; 58% were resistant to TMP-SMX and 50% to tetracycline, but none presented erythromycin or chloramphenicol resistance. The remaining 20 isolates could be grouped into 12 different PFGE types; ILR was shown in 75% of isolates, 70% were resistant to TMP-SMX and to tetracycline, 15% were resistant to erythromycin, and none were resistant to chloramphenicol. These data suggest that some Colombian isolates are clonally related to two of the well-known international epidemic S. pneumoniae clones.

Entities:  

Mesh:

Year:  1998        PMID: 9818975     DOI: 10.1089/mdr.1998.4.233

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  6 in total

1.  Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network.

Authors:  L McGee; L McDougal; J Zhou; B G Spratt; F C Tenover; R George; R Hakenbeck; W Hryniewicz; J C Lefévre; A Tomasz; K P Klugman
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

2.  Dissemination of Streptococcus pneumoniae clone Colombia(5)-19 in Latin America.

Authors:  Liliana Gamboa; Teresa Camou; María Hortal; Elizabeth Castañeda
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

3.  Molecular evolution in a multidrug-resistant lineage of Streptococcus pneumoniae: emergence of strains belonging to the serotype 6B Icelandic clone that lost antibiotic resistance traits.

Authors:  S E Vilhelmsson; A Tomasz; K G Kristinsson
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

4.  Dissemination of a chloramphenicol- and tetracycline-resistant but penicillin-susceptible invasive clone of serotype 5 Streptococcus pneumoniae in Colombia.

Authors:  M Tamayo; R Sá-Leão; I Santos Sanches; E Castañeda; H de Lencastre
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

5.  Molecular epidemiology of penicillin-susceptible non-beta-lactam-resistant Streptococcus pneumoniae isolates from Greek children.

Authors:  D Bogaert; P W M Hermans; I N Grivea; G S Katopodis; T J Mitchell; M Sluijter; R De Groot; N G Beratis; G A Syrogiannopoulos
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

6.  Pneumococcal surface protein A of invasive Streptococcus pneumoniae isolates from Colombian children.

Authors:  M C Vela Coral; N Fonseca; E Castañeda; J L Di Fabio; S K Hollingshead; D E Briles
Journal:  Emerg Infect Dis       Date:  2001 Sep-Oct       Impact factor: 6.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.